Tsourapas Panagiotis

COO Tsourapas sold 50,000 CL shares across 2 days for $4,778,436.50; reduced holdings 82.8% to 10.4K shares post-transaction.

Tsourapas executed two separate sales totaling 50,000 shares (50.0K shares) for $4,778,436.50, reducing his Colgate-Palmolive holdings from 60,415 to 10,415 shares—an 82.8% reduction in position size. The blended average price of $95.57 compares favorably to the current price of $96.67 and is -0.8% from the 52-week high of $97.50, placing the sale near peak valuation. His prior five sales at CL show mixed timing: 3 of 5 achieved negative 90-day returns (well-timed), while 2 achieved positive 90-day returns (poorly timed), indicating no consistent directional edge at this ticker. The stock has gained 14.3% over 30 days and 23.9% over 90 days, so post-transaction performance cannot yet be assessed. Given the magnitude of the position reduction and the COO's operational role (Eur., APac, Afr regions), this substantial liquidation warrants monitoring for any signals about management confidence, though the sale price near 52-week highs does not inherently suggest bearish conviction.

Group President, Europe & Developing Markets sold 20.0K shares of CL at $93.30 on 2024-11-04 for $1.9M, reducing holdings -28.9%

Tsourapas Panagiotis, Group President of Europe & Developing Markets, executed a material sale of 20,032 shares on 2024-11-04 at $93.30, reducing his stake from 69.2K to 49.2K shares—a -28.9% reduction in his post-transaction holdings. The sale occurred when CL was trading near its recent range but down 13.3% from the 52-week high and -4.8% over the prior 30 days, suggesting a liquidation during a period of price weakness. His same-ticker history at CL shows mixed timing outcomes: only 1 of 4 prior measurable sales (25%) were well-timed at the 90-day mark, with his most recent CL sale on 2024-08-08 delivering +4.8% return in 30 days but an unclear 90-day outcome. While the sale's absolute dollar magnitude ($1.9M) is material and the insider retained 49.2K shares post-transaction, the pattern of frequent sequential sells at this ticker without strong predictive timing accuracy does not establish a compelling signal of forward-looking concern about the company's fundamentals.

Group President Tsourapas sells 14.8K CL shares at $102.94; reduces stake by 74.2% to 5.1K shares

Tsourapas, Group President for Europe & Developing Markets, sold 14,794 shares on 2024-08-08 at $102.94, reducing his holdings from 19,940 to 5,146 shares—a 74.2% reduction in his position. At the time of sale, CL was trading near its 52-week high of $102.81 and has since declined 1.5% to the current price of $101.28. Notably, his prior four measurable sales at CL each saw positive 90-day returns (+8.8%, +8.9%, +10.7%, +11.8%), meaning the stock rose after those sales—a pattern of poorly-timed exits. This transaction does not follow that unfavorable pattern, as CL has declined modestly post-trade, but the large reduction in stake warrants investor attention to understand the business rationale behind the disproportionate liquidation.

Tsourapas (Grp Pres, Eur & Dev Mkts) sold 40,000 CL shares at $99.47; now holds 5,146 shares (-88.6%).

Tsourapas sold 40,000 shares (88.6% of pre-transaction holdings) on 2024-07-31, reducing his stake to 5,146 shares. The transaction occurred at $99.47, which was $3.34 below the current price of $102.81 and 3.3% below the 52-week high. His same-ticker history at CL shows mixed outcomes: 4 of 5 prior sells had measurable 90-day returns, with only 1 of 4 being well-timed (negative 90-day return). His cross-ticker track record shows a 57.14% well-timed rate across 8 prior sells, but this particular sale follows a pattern where he sold 40,000 shares in May 2024 (30 days before this filing data), and the stock has since appreciated 7.2% over 30 days and 10.7% over 90 days. The near-total liquidation of a regional president's holdings in a stable consumer staples company with $84.0B market cap, +8.3% annual revenue growth, and $731.0M net income warrants tracking whether this reflects portfolio rebalancing or shifting personal circumstances rather than fundamental concerns about the business.